TABLE 2.
Pharmacokinetic/pharmacodynamic model parameters
| Parameter | Parameter estimate |
Between-subject variability |
||
|---|---|---|---|---|
| Value | RSEa (%) | CVb (%) | RSE (%) | |
| SP PD model | ||||
| Baseline logit | −0.441 | 39 | 115 | 14 |
| Primigravida baseline logitc | 0.511 | 78 | ||
| Indoor residual spraying | −0.72 | 60 | ||
| Dry season | −1.13 | 28 | ||
| DHA-PQ PK/PD model for parasitemia | ||||
| Baseline logit | −0.508 | 72 | 73 | 17 |
| Primigravida baseline logitc | 0.582 | 64 | ||
| Slope of concentration-dependent effect (ml/ng) | −0.204 | 16 | ||
| Indoor residual spraying | −10 fixed | |||
| Third trimester | −1.45 | 45 | ||
| DHA-PQ PK/PD model for pfmdr1 N86Y | ||||
| Baseline logit | −1.16 | 11 | 3.8 | 53 |
| Slope of concentration-dependent effect | 0.317 | 21 | ||
| DHA-PQ PK/PD for pfcrt K76T | ||||
| Baseline logit | 1.06 | 11 | 2.2 | 22 |
| Slope of concentration-dependent effect | 0.218 | 22 | ||
a
RSE, relative standard error.
b
CV, coefficient of variation.
c
Baseline logit used for all gravidities after start of IPTp, as gravidity was not a significant predictor of parasitemia after the start of chemoprevention.